Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Accounts Payables: 2016-2025

Historic Accounts Payables for UroGen Pharma (URGN) over the last 9 years, with Sep 2025 value amounting to $26.2 million.

  • UroGen Pharma's Accounts Payables rose 32.96% to $26.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.2 million, marking a year-over-year increase of 32.96%. This contributed to the annual value of $27.4 million for FY2024, which is 65.87% up from last year.
  • Latest data reveals that UroGen Pharma reported Accounts Payables of $26.2 million as of Q3 2025, which was down 15.47% from $31.0 million recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Accounts Payables registered a high of $31.0 million during Q2 2025, and its lowest value of $8.6 million during Q2 2022.
  • In the last 3 years, UroGen Pharma's Accounts Payables had a median value of $19.7 million in 2024 and averaged $21.9 million.
  • In the last 5 years, UroGen Pharma's Accounts Payables fell by 16.39% in 2022 and then soared by 89.70% in 2023.
  • Quarterly analysis of 5 years shows UroGen Pharma's Accounts Payables stood at $12.1 million in 2021, then grew by 2.32% to $12.4 million in 2022, then soared by 33.55% to $16.5 million in 2023, then spiked by 65.87% to $27.4 million in 2024, then surged by 32.96% to $26.2 million in 2025.
  • Its Accounts Payables stands at $26.2 million for Q3 2025, versus $31.0 million for Q2 2025 and $30.3 million for Q1 2025.